Servier to buy Edgewise's muscular dystrophy business for $2.65bn

Servier has signed an agreement to acquire Edgewise Therapeutics’ muscular dystrophy business in a deal valued at up to $2.65bn. The companies anticipate finalising the acquisition in the third quarter of 2026. The acquisition aligns with Servier’s strategic goal in rare neurology. Credit: Vernerie Yann / Shutterstock.com. Servier has signed an agreement to acquire Edgewise Therapeutics’ muscular dystrophy business in a deal valued at up to $2.65bn. The value includes a $1.55bn upfront payment and as much as $1.1bn in regulatory and commercial milestone payments. LOA and PTSR Model EDG-5506 in Becker Muscular Dystrophy Reports LOA and PTSR Model…

Source: Pharmaceutical Technology